



THE UNIVERSITY OF ARIZONA
COLLEGE OF MEDICINE TUCSON

Pharmacology

Presents

“A Bench to Bedside and Back Again Approach Targeting the EWS-FLI1 Transcription Factor for Ewing Sarcoma”

BY



Patrick J. Grohar, MD, PhD
Director, Translational Research, Center for Childhood
Cancer Research, Division of Oncology, Children’s
Hospital of Philadelphia
Kelly and Chad PUNCHARD Endowed Chair of Translational
Sarcoma Research
Associate Professor of Pediatrics, Perelman School of
Medicine at the University of Pennsylvania

Abstract: Ewing sarcoma is the second most common malignant bone tumor of childhood. This tumor has a low somatic mutation frequency and an absolute dependence on the EWS-FLI1 transcription factor for cell survival. Unfortunately, EWS-FLI1 is a transcription factor and a challenging drug target. Our group has spent the last 15 years focused on the therapeutic targeting of EWS-FLI1. We employ a bench to bedside and back again approach that leverages molecular pharmacology and genomics to develop and clinically translate targeted therapies focused on EWS-FLI1. In this lecture, I will discuss the clinical development and mechanism of action of the DNA binding natural products trabectedin, mithramycin, and analogs as EWS-FLI1 targeted agents.

Wednesday, March 20, 2024

11:00 am – Noon

AHSC - Room 8403

<https://arizona.zoom.us/j/87382571358>